HC Wainwright Has Bullish Estimate for FDMT FY2027 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Stock analysts at HC Wainwright lifted their FY2027 earnings estimates for 4D Molecular Therapeutics in a research report issued on Friday, August 14th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($4.34) for the year, up from their previous forecast of ($4.40). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ FY2028 earnings at ($4.12) EPS, FY2029 earnings at ($2.72) EPS and FY2030 earnings at ($1.52) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million.

FDMT has been the subject of a number of other research reports. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. The Goldman Sachs Group reissued a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, B. Riley Financial reissued a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $29.62.

4D Molecular Therapeutics Trading Up 19.4%

FDMT opened at $14.55 on Tuesday. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics has a 52 week low of $5.97 and a 52 week high of $15.03. The stock has a market cap of $760.67 million, a PE ratio of -5.53 and a beta of 2.73. The business has a 50 day moving average of $11.06 and a 200-day moving average of $9.93.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider David Kirn sold 114,746 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider owned 942,485 shares of the company’s stock, valued at $9,867,817.95. The trade was a 10.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the transaction, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. This represents a 53.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 200,496 shares of company stock worth $2,240,244 in the last quarter. Corporate insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in FDMT. Legal & General Group Plc purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter worth approximately $59,000. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics in the third quarter worth approximately $41,000. Daiwa Securities Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 3,362.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after purchasing an additional 6,186 shares in the last quarter. Susquehanna Portfolio Strategies LLC bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at $77,000. Finally, Martingale Asset Management L P raised its position in shares of 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares during the period. 99.27% of the stock is currently owned by institutional investors.

Trending Headlines about 4D Molecular Therapeutics

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: Analysts remain constructive: HC Wainwright reiterated a Buy rating with a $36 price target, while the broader analyst consensus is “Moderate Buy” with an average target of $29.62. Goldman Sachs also maintained a Buy rating and a $32 target. These targets imply substantial potential upside from recent trading levels. Analyst ratings and price targets
• Positive Sentiment: Institutional interest has strengthened, with Bank of America, Man Group, Jupiter Topco and other investors establishing positions during the second quarter. Institutions collectively own approximately 99.27% of FDMT’s outstanding shares, signaling strong professional-investor participation. Institutional investment and stock performance article
• Positive Sentiment: FDMT recently reached a new 12-month high, with its market momentum supported by a share price well above its 50-day and 200-day moving averages. 4D Molecular Therapeutics reaches 12-month high
• Neutral Sentiment: HC Wainwright’s earnings revisions were mixed: its FY2027 loss estimate improved modestly to $4.34 per share from $4.40, but projected losses for FY2028 through FY2030 widened slightly. The revisions indicate a longer path to profitability despite the firm’s bullish rating.
• Negative Sentiment: Insider Scott Bizily sold 1,635 shares for approximately $19,620 at an average price of $12.00, reducing his direct holdings by 15.95%. A separate filing also reported a comparable sale at $12.20. Repeated insider selling may weigh on sentiment, although the transactions are relatively small. 4D Molecular Therapeutics insider sale
• Negative Sentiment: 4D Molecular Therapeutics recently reported a quarterly loss of $1.04 per share, slightly worse than the $1.02 analyst consensus. Revenue of $3.78 million modestly exceeded estimates, but the company’s negative net margin and projected full-year loss of $3.88 per share underscore ongoing profitability and execution risks.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.